InvestigatioN of a Smart Probe for Lung lEsion Characterization Using Impedance Technology

Lung Cancer Clinical Trial

— INSPECT  

Official title:

InvestigatioN of a Smart Probe for Lung lEsion Characterization Using Impedance Technology

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06380361
• Other study ID #: SEN-ONCO-1
• Status: Recruiting
• Phase: N/A
• Start date: March 28, 2024
• Est. completion date: April 1, 2025

Study information

• Verified date: April 2024
• Source: Sensome
• Contact: Julie Lafaurie, PhD
• Phone: + 33 1 85 37 07 70
• Email: julie[@]sensome.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of the study is to evaluate the feasibility of the BioSpy System sensor to differentiate tissues that are encountered during bronchoscopic biopsy of endobronchial tumors and peripheral lung nodules and masses.

Description:

Participants in this study require a lung biopsy to confirm if they have a lung tumour. A biopsy is a procedure where a piece of lung tissue is removed for testing. Current biopsy techniques cannot guarantee the exact location of lung tumours, so biopsies can be taken from healthy tissue.

The BioSpy System (BSS) is a device with a probe, which is placed inside a normal biopsy needle. The tip of the probe contains sensors, that will scan the composition of the tissue which is in contact with the sensors.

The INSPECT study aims at collecting the sensor data, with the goal of being able to differentiate the different tissues.

All study participants will have a biopsy with the BSS. Participants will have a hospital visit for the procedure, and will have to stay up to 16 hours after their procedure as per normal hospital practice.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: April 1, 2025
• Est. primary completion date: March 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age > 18 years

2. Subjects with lesions eligible for lung biopsy under general anesthesia.

3. Lesion localization:

1. Central or proximal lesions = 10 mm in diameter confirmed by imaging (CT scan and/or PET scan) and/or endobronchial visual control; or

2. Peripheral lesions = 20 mm in diameter confirmed by imaging (CT scan and/or PET scan) and/or ultrasound analysis (RP EBUS with central localization of the ultrasound probe) during the procedure.

4. Written Informed Consent to participate in the study.

Exclusion Criteria:

1. Target lesion <10 mm for central and <20 mm for peripheral lesions (as determined on previous imaging)

2. Contra-indication to bronchoscopy procedures

3. Contra-indication to general anesthesia

4. Any subject that is, according to the discretion of the investigator, not eligible for study participation

5. Known lactating or confirmation of positive pregnancy test according to site specific standard of care (e.g. test, verbal communication)

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Intervention

Device:
• BioSpy System
One arm only - in all eligible study patients, the study device will be used. In patients with suspicion of lung cancer a bronchoscope will be inserted to navigate to the lesion where a biopsy sample will be taken for histology analysis. In the current trial, the device will be used to perform electrophysiological measurements in the lesion during bronchoscopic biopsy procedure.

Locations

Country	Name	City	State
Australia	Royal Brisbane and Women's Hospital	Brisbane	Queensland

Sponsors (1)

Lead Sponsor	Collaborator
Sensome

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The ability of BioSpy System to acquire electrophysiological measurements in the relevant tissues during bronchoscopic biopsy.	This endpoint represents the procedural success rate being defined as the BioSpy System obtaining at least one non-anomalous impedance measurement in the lesion during the procedure.	During the bronchoscopic biopsy procedure
Secondary	The ability of BioSpy Sysem to differentiate the lesion from healthy tissue	The ability of BioSpy Sysem (BSS) to differentiate the lesion (nodule or mass) from healthy tissue (bronchial tissue, lung parenchyma, …) by means of the impedance measurements.; These impedance measurements of the BSS will be compared to the physician's assessment based on available imaging (visual control, ultrasound, fluoroscopy etc…) for verification.; The ability to differentiate tissues will be reported by descriptive statistics.; To further assess this secondary endpoint, Machine Learning analysis will be applied.; Following standard procedure, features will be extracted from the impedance measurements and used for model inference.	During the bronchoscopic biopsy procedure
Secondary	The ability of BioSpy Sysem to differentiate various lesion types	The ability of BioSpy Sysem to differentiate various lesion types such as, but not limited to: Tumoral tissue; Inflamed tissue; Necrotic tissue; Fibrosis The impedance measurements of BSS in the lesion will be compared to the histopathology analysis of the collected tissue during the biopsy.; The ability to differentiate tissues will be reported by descriptive statistics.; To further assess this secondary endpoint, Machine Learning analysis will be applied.; Following standard procedure, features will be extracted from the impedance measurements and used for model inference.	During the procedure